I knew a guy who lost it all in 1973 being short the wrong thing when the news came out against him. He lost millions, then his wife, then his life. It was very sad to see as a new broker.
"Thus, blocking CCR5/CCL5 axis might prove beneficial to prevent metastasis and provide a more therapeutic strategy to control Pancreatic cancer progression." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778036/
"Glioblastoma (GBM) is the most prevalent malignant primary brain tumor in adults and exhibits a spectrum of aberrantly aggressive phenotype.Recent studies have shown that the chemokine CCL5 and its receptor CCR5 play important roles in tumor invasion and metastasis." https://www.ncbi.nlm.nih.gov/m/pubmed/26390883/
And so 22 types of cancers where CCR5 is over expressed, Leronlimab successfully blocks CCR5 without SAE on over 840 patients with HIV-1, some have been on Leronlimab for 5 years.
I covered once at .92 and re-shorted more. Covered again on that fall from 1.54 to 1.25 the other day. Decent return. Just checked . Currently at 36,525 shares short. Not cleaning up but green now.